CEL-SCI CORP Files 8-K Under 'Other Events'
Ticker: CVM · Form: 8-K · Filed: Aug 25, 2025 · CIK: 725363
Sentiment: neutral
Topics: 8-k, other-events
TL;DR
CEL-SCI filed an 8-K for an 'Other Event' on Aug 22. Details TBD.
AI Summary
CEL-SCI CORPORATION filed an 8-K on August 25, 2025, reporting an event that occurred on August 22, 2025. The filing is categorized under 'Other Events' and does not provide specific details about the nature of the event, dollar amounts, or names involved.
Why It Matters
This 8-K filing indicates a material event has occurred for CEL-SCI CORPORATION, but the lack of detail requires further investigation to understand its implications.
Risk Assessment
Risk Level: medium — The filing is an 8-K, indicating a significant event, but the 'Other Events' category and lack of specific details create uncertainty.
Key Players & Entities
- CEL-SCI CORPORATION (company) — Registrant
- August 22, 2025 (date) — Date of earliest event reported
- August 25, 2025 (date) — Date of report
- 7035069460 (phone_number) — Registrant's telephone number
FAQ
What specific event is CEL-SCI CORPORATION reporting under 'Other Events'?
The filing does not specify the nature of the event reported under 'Other Events'.
When did the event reported in the 8-K filing occur?
The earliest event reported occurred on August 22, 2025.
What is the filing date of this 8-K report?
The report was filed as of August 25, 2025.
What is CEL-SCI CORPORATION's principal executive office address?
The principal executive offices are located at 8229 Boone Blvd. #802, Vienna, VA 22182.
What is the SIC code for CEL-SCI CORPORATION?
The Standard Industrial Classification (SIC) code is 2836 for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 566 words · 2 min read · ~2 pages · Grade level 13.3 · Accepted 2025-08-22 18:00:42
Key Financial Figures
- $0.01 — ch Registered Common Stock, par value $0.01 per share CVM NYSE American Indica
Filing Documents
- cvm_8k.htm (8-K) — 22KB
- 0001654954-25-009966.txt ( ) — 131KB
- cvm-20250822.xsd (EX-101.SCH) — 5KB
- cvm-20250822_lab.xml (EX-101.LAB) — 14KB
- cvm-20250822_cal.xml (EX-101.CAL) — 1KB
- cvm-20250822_pre.xml (EX-101.PRE) — 9KB
- cvm-20250822_def.xml (EX-101.DEF) — 2KB
- cvm_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. CEL-SCI Corporation recently reported that a Breakthrough Medicine Designation application was filed with the Saudi Food and Drug Authority (SFDA) for Multikine (Leukocyte Interleukin, Injection) in the Kingdom of Saudi Arabia by one of the Kingdom's premier pharmaceutical and healthcare companies. This pharma company is Dallah Pharma, a subsidiary of Dallah Healthcare Company (Saudi Stock Exchange Tadawul, Symbol: 4004). CEL-SCI has signed a Memorandum of Understanding (MOU) with Dallah Pharma for the commercialization of Multikine in Saudi Arabia. A final partnership agreement is expected during the 3rd quarter of 2025. Dallah Healthcare Company serves over three million patients annually through an extensive network of hospitals and specialized clinics, in addition to home care services. Relying on a highly experienced team and a distinguished group of specialized physicians, Dallah Healthcare Company operates according to the highest standards of quality and patient safety. Dallah Health remains committed to the humanitarian and professional values that have made it the leading reference for trusted healthcare in the Kingdom. According to the SFDA, the response time to a Breakthrough Medicine Designation application is approximately 60 days. Following the granting of Breakthrough Medicine Designation, Multikine would immediately become available for patient access and reimbursement/sale in Saudi Arabia. Dallah Pharma is well positioned to procure reimbursement and to accelerate Multikine's sale and commercial launch. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 22, 2025 CEL-SCI CORPORATION By: /s/ Geert Kersten Geert Kersten Chief Executive Officer 3